A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia
Copyright 2003 Massachusetts Medical Society.
OBJECTIVE: Magnesium sulfate may prevent eclampsia by reducing cerebral vasoconstriction and ischemia. Nimodipine is a calcium-channel blocker with specific cerebral vasodilator activity. Our objective was to determine whether nimodipine is more effective than magnesium sulfate for seizure prophylaxis in women with severe preeclampsia.
METHODS: We conducted an unblinded, multicenter trial in which 1650 women with severe preeclampsia were randomly assigned to receive either nimodipine (60 mg orally every 4 hours) or intravenous magnesium sulfate (given according to the institutional protocol) from enrollment until 24 hours post partum. High blood pressure was controlled with intravenous hydralazine as needed. The primary outcome measure was the development of eclampsia, as defined by a witnessed tonic-clonic seizure.
RESULTS: Demographic and clinical characteristics were similar in the two groups. The women who received nimodipine were more likely to have a seizure than those who received magnesium sulfate (21 of 819 [2.6 percent] vs. 7 of 831 [0.8 percent], P=0.01). The adjusted risk ratio for eclampsia associated with nimodipine, as compared with magnesium sulfate, was 3.2 (95 percent confidence interval, 1.1 to 9.1). The antepartum seizure rates did not differ significantly between groups, but the nimodipine group had a higher rate of postpartum seizures (9 of 819 [1.1 percent] vs. 0 of 831, P=0.01). There were no significant differences in neonatal outcome between the two groups. More women in the magnesium sulfate group than in the nimodipine group needed hydralazine to control blood pressure (54.3 percent vs. 45.7 percent, P<0.001).
CONCLUSIONS: Magnesium sulfate is more effective than nimodipine for prophylaxis against seizures in women with severe preeclampsia.
| Errataetall: |
CommentIn: N Engl J Med. 2003 Jan 23;348(4):275-6. - PMID 12540639 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2003 |
|---|---|
| Erschienen: |
2003 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:348 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 348(2003), 4 vom: 23. Jan., Seite 304-11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Belfort, Michael A [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 27.01.2003 Date Revised 21.11.2013 published: Print CommentIn: N Engl J Med. 2003 Jan 23;348(4):275-6. - PMID 12540639 Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM123219876 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM123219876 | ||
| 003 | DE-627 | ||
| 005 | 20231222200909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231222s2003 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0411.xml |
| 035 | |a (DE-627)NLM123219876 | ||
| 035 | |a (NLM)12540643 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Belfort, Michael A |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia |
| 264 | 1 | |c 2003 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.01.2003 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: N Engl J Med. 2003 Jan 23;348(4):275-6. - PMID 12540639 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2003 Massachusetts Medical Society | ||
| 520 | |a OBJECTIVE: Magnesium sulfate may prevent eclampsia by reducing cerebral vasoconstriction and ischemia. Nimodipine is a calcium-channel blocker with specific cerebral vasodilator activity. Our objective was to determine whether nimodipine is more effective than magnesium sulfate for seizure prophylaxis in women with severe preeclampsia | ||
| 520 | |a METHODS: We conducted an unblinded, multicenter trial in which 1650 women with severe preeclampsia were randomly assigned to receive either nimodipine (60 mg orally every 4 hours) or intravenous magnesium sulfate (given according to the institutional protocol) from enrollment until 24 hours post partum. High blood pressure was controlled with intravenous hydralazine as needed. The primary outcome measure was the development of eclampsia, as defined by a witnessed tonic-clonic seizure | ||
| 520 | |a RESULTS: Demographic and clinical characteristics were similar in the two groups. The women who received nimodipine were more likely to have a seizure than those who received magnesium sulfate (21 of 819 [2.6 percent] vs. 7 of 831 [0.8 percent], P=0.01). The adjusted risk ratio for eclampsia associated with nimodipine, as compared with magnesium sulfate, was 3.2 (95 percent confidence interval, 1.1 to 9.1). The antepartum seizure rates did not differ significantly between groups, but the nimodipine group had a higher rate of postpartum seizures (9 of 819 [1.1 percent] vs. 0 of 831, P=0.01). There were no significant differences in neonatal outcome between the two groups. More women in the magnesium sulfate group than in the nimodipine group needed hydralazine to control blood pressure (54.3 percent vs. 45.7 percent, P<0.001) | ||
| 520 | |a CONCLUSIONS: Magnesium sulfate is more effective than nimodipine for prophylaxis against seizures in women with severe preeclampsia | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Calcium Channel Blockers |2 NLM | |
| 650 | 7 | |a Vasodilator Agents |2 NLM | |
| 650 | 7 | |a Magnesium Sulfate |2 NLM | |
| 650 | 7 | |a 7487-88-9 |2 NLM | |
| 650 | 7 | |a Nifedipine |2 NLM | |
| 650 | 7 | |a I9ZF7L6G2L |2 NLM | |
| 700 | 1 | |a Anthony, John |e verfasserin |4 aut | |
| 700 | 1 | |a Saade, George R |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, John C |c Jr |e verfasserin |4 aut | |
| 700 | 0 | |a Nimodipine Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 348(2003), 4 vom: 23. Jan., Seite 304-11 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:348 |g year:2003 |g number:4 |g day:23 |g month:01 |g pages:304-11 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 348 |j 2003 |e 4 |b 23 |c 01 |h 304-11 | ||